Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?
Open Access
- 1 December 1993
- Vol. 70 (6), 530-536
- https://doi.org/10.1136/hrt.70.6.530
Abstract
OBJECTIVE--To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabetic patients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy. DESIGN--Prospective study of patients admitted with acute myocardial infarction. SETTING--District general hospital. MAIN OUTCOME MEASURES--Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme. RESULTS--Baseline PAI-1 activity and antigen concentrations were significantly higher in diabetic patients (n = 45) than in non-diabetic patients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabetic patients (n = 26) and 12 h (5-26 h) in non-diabetic patients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032). CONCLUSION--Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabetic patients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.Keywords
This publication has 42 references indexed in Scilit:
- Indices of reperfusion in patients with acute myocardial infarction using characteristics of the CK-MB time-activity curveAmerican Heart Journal, 1991
- Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic PatientsDiabetic Medicine, 1991
- Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarctionThe American Journal of Cardiology, 1989
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarctionThe American Journal of Cardiology, 1987
- Arteriographic predictors of spontaneous improvement in left ventricular function after myocardial infarction.Circulation, 1985
- Why do diabetic patients die after myocardial infarction?Practical Diabetes International, 1984
- Left Ventricular Function and Rapid Release of Creatine Kinase MB in Acute Myocardial InfarctionNew England Journal of Medicine, 1983
- Intravenous short-term infusion of streptokinase in acute myocardial infarction.Circulation, 1983
- Estimation of Infarct Size in Man and its Relation to PrognosisCirculation, 1972